Abstract
Alzheimers disease is a devastating degenerative disorder for which there is no cure or effective treatment. Although the etiology of Alzheimers disease is not fully understood, compelling evidence indicates that deposition of aggregates composed by a misfolded form of the amyloid beta peptide (Aβ) is the central event in the disease pathogenesis. Therefore, an attractive therapeutic strategy is to prevent or reverse Aβ misfolding and aggregation. Diverse strategies have been described to identify inhibitors of this process, including screening of libraries of small molecules chemical compounds, rational design of synthetic peptides, assessment of natural Aβ-binding proteins and stimulation of the immune system by vaccination. In this article we describe these different approaches, their principles and their potential strengths and weaknesses. Overall the available data suggest that the development of drugs to interfere with Aβ misfolding and aggregation is a feasible target that hold great promise for the treatment of Alzheimers disease.
Keywords: Aggregation inhibitors, β-sheet breakers, amyloid, Alzheimer's disease
Current Topics in Medicinal Chemistry
Title: Disrupting β-Amyloid Aggregation for Alzheimer Disease Treatment
Volume: 7 Issue: 1
Author(s): L. D. Estrada and C. Soto
Affiliation:
Keywords: Aggregation inhibitors, β-sheet breakers, amyloid, Alzheimer's disease
Abstract: Alzheimers disease is a devastating degenerative disorder for which there is no cure or effective treatment. Although the etiology of Alzheimers disease is not fully understood, compelling evidence indicates that deposition of aggregates composed by a misfolded form of the amyloid beta peptide (Aβ) is the central event in the disease pathogenesis. Therefore, an attractive therapeutic strategy is to prevent or reverse Aβ misfolding and aggregation. Diverse strategies have been described to identify inhibitors of this process, including screening of libraries of small molecules chemical compounds, rational design of synthetic peptides, assessment of natural Aβ-binding proteins and stimulation of the immune system by vaccination. In this article we describe these different approaches, their principles and their potential strengths and weaknesses. Overall the available data suggest that the development of drugs to interfere with Aβ misfolding and aggregation is a feasible target that hold great promise for the treatment of Alzheimers disease.
Export Options
About this article
Cite this article as:
Estrada D. L. and Soto C., Disrupting β-Amyloid Aggregation for Alzheimer Disease Treatment, Current Topics in Medicinal Chemistry 2007; 7 (1) . https://dx.doi.org/10.2174/156802607779318262
DOI https://dx.doi.org/10.2174/156802607779318262 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ionophores as Potent Anti-malarials: A Miracle in the Making
Current Topics in Medicinal Chemistry Serum Collagen Markers and Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Carnitine Metabolism and Deficit - When Supplementation is Necessary?
Current Pharmaceutical Biotechnology Contribution of ALDH2 Polymorphism to Alcoholism-Associated Hypertension
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Zinc, Metallothioneins and Longevity: Interrelationships with Niacin and Selenium
Current Pharmaceutical Design Bisphenol A as a Factor in the Mosaic of Autoimmunity
Endocrine, Metabolic & Immune Disorders - Drug Targets MicroRNAs in the Management of Heart Failure
Current Medicinal Chemistry Editorial [Hot Topic: Vascular Complications of Diabetes (Executive Editor: Olga I. Stenina)]
Current Pharmaceutical Design Editorial (Thematic Issue: Mechanistic Biomarkers: The Field for the Development of Non-Pharmaceutical and Pharmaceutical Approaches to Diagnostics, Prevention and Treatment of Chronic Diseases)
Current Pharmaceutical Design Adenosine Receptors: What We Know and What We are Learning
Current Topics in Medicinal Chemistry Clinical and Molecular Genetic Aspects of Hypertrophic Cardiomyopathy
Current Cardiology Reviews The Potential of Secondary Metabolites from Plants as Drugs or Leads Against Protozoan Neglected Diseases – Part I
Current Medicinal Chemistry Neurodevelopmental Delay and Intellectual Disability in Pediatric Heart Transplant
Current Psychiatry Reviews Nicotine Addiction and Coronary Artery Disease: Impact of Cessation Interventions
Current Pharmaceutical Design Potential Roles of MyomiRs in Cardiac Development and Related Diseases
Current Cardiology Reviews Evaluation of Gene and Cell-Based Therapies for Cardiac Regeneration
Current Stem Cell Research & Therapy Trypanosomatid Parasites Causing Neglected Diseases
Current Medicinal Chemistry Targeting the EGFR-family for Therapy: Biological Challenges and Clinical Perspective
Current Pharmaceutical Design Oxidative stress and myocarditis
Current Pharmaceutical Design Models and Methods in Cardiac Imaging for Metabolism Studies
Current Pharmaceutical Design